Blood Cancers Today
@blood_cancers
Translating Hematologic Oncology Discoveries into Practice.
ID: 1443228030093209607
http://www.bloodcancerstoday.com/ 29-09-2021 14:56:00
3,3K Tweet
1,1K Takipçi
265 Takip Edilen
The FDA ODAC voted in favor of the use of MRD-negativity as an endpoint for accelerated approval in #myeloma trials. Read more about the vote, with remarks from Chris Hourigan (Fralin Biomedical Research Institute), Ravi A Madan M.D. (National Cancer Institute), & Matthew J. Maurer, DMSc (Mayo Clinic). 📖 buff.ly/4aF8oxb